ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Pituitary Endocrinology

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1539797

Biomarkers of GH Deficiency Identified in Untreated and GH-Treated Pit-1 Mutant Mice

Provisionally accepted
Sarmed  Al-SamerriaSarmed Al-Samerria1*Huiting  XuHuiting Xu2M. Elena  Diaz RubioM. Elena Diaz Rubio3Joseph  PhelanJoseph Phelan2Chi  SuChi Su2Keer  MaKeer Ma2Anna  NewenAnna Newen2Kiana  LiKiana Li2Sayaka  YamadaSayaka Yamada4Ariel  L NegronAriel L Negron1Fredric  WondisfordFredric Wondisford4Sally  RadovickSally Radovick1
  • 1Department of Pediatrics, College of Medicine, University of Arizona, Tucson, Arizona, United States
  • 2Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States
  • 3Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States
  • 4College of Medicine Phoenix, University of Arizona, Phoenix, Arizona, United States

The final, formatted version of the article will be published soon.

Background: Growth Hormone Deficiency (GHD) is marked by insufficient growth hormone (GH) production, leading to disruptions in growth and metabolism. Its diagnosis is challenging due to the lack of sensitive, specific tests. To address this, we used a novel mouse model with a POU1F1 (Pit-1) gene mutation (K216E). This study aimed to identify metabolic biomarkers of GHD and assess their responsiveness to GH therapy, alongside pathway analysis to uncover disrupted metabolic pathways.The Pit-1 ^K216E mouse model was validated for GHD through assessments of GH production, growth, and body composition. Metabolomic profiling was conducted to identify biomarkers, while pathway analysis examined disrupted metabolic pathways and their response to GH treatment. This approach aimed to improve understanding of GHD's metabolic impact and potential therapeutic strategies.The assessment of the Pit-1 ^K216E mouse confirmed GHD, as evidenced by reduced GH production and altered body composition. Metabolomic profiling identified three distinct biomarker groups associated with GHD: (1) GHD Biomarkers, found exclusively in GH-deficient mutant mice but absent in WT controls; (2) GH Treatment Responsive Biomarkers, which were altered in GH-deficient mutant mice (GHD) and further modulated following GH treatment, reflecting a response specific to the GHD condition and its treatment, but not observed in WT mice; and (3) GH Treatment-Specific Responsive Biomarkers, observed exclusively in the GHD condition after GH therapy. Pathway analysis revealed significant disruptions in purine metabolism, amino acid metabolism, and protein synthesis, with notable sex-specific differences.Male mice exhibited imbalances in taurine and hypotaurine metabolism, while female mice showed disruptions in tyrosine metabolism and mitochondrial function, highlighting sexdependent metabolic responses to GHD and GH therapy.The Pit-1 ^K216E mouse model offers a robust platform for exploring GHD's molecular mechanisms. The identification of distinct, sex-specific metabolic biomarkers provides insights into GHD-related metabolic disruptions and supports personalized management strategies. These findings establish a framework for leveraging metabolic biomarkers to enhance the diagnosis and monitoring of GHD, with promising applications for future human studies and therapeutic strategies.

Keywords: growth hormone deficiency, biomarkers, PIT-1 mutation, Metabolomics, GH treatment, Energy Metabolism, sex differences

Received: 04 Dec 2024; Accepted: 13 Mar 2025.

Copyright: © 2025 Al-Samerria, Xu, Diaz Rubio, Phelan, Su, Ma, Newen, Li, Yamada, Negron, Wondisford and Radovick. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Sarmed Al-Samerria, Department of Pediatrics, College of Medicine, University of Arizona, Tucson, 85724, Arizona, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more